<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36930071</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>18</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>102</Volume><Issue>11</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>17</Day></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>The association between C509T, T869C, G915C gene polymorphisms of transforming growth factor-&#x3b2;1 and systemic lupus erythematosus risk: A meta-analysis.</ArticleTitle><Pagination><StartPage>e33321</StartPage><MedlinePgn>e33321</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e33321</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000033321</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The relationship between transforming growth factor-&#x3b2;1 (TGF- &#x3b2;1) gene polymorphisms and systemic lupus erythematosus (SLE) has been reported in many studies, but there were still controversies with regard to their conclusions.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Relevant documents were retrieved from 5 electronic databases such as PubMed, Embase, Cochrane Library, Wanfang, and China national knowledge infrastructure. Odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were used to assess the relationship between TGF-&#x3b2;1 genetic variation and SLE.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The present meta-analysis included 12 case-control studies with 1308 SLE patients and 1714 healthy controls. The results of the combined analyses showed that TGF-&#x3b2;1 C509T polymorphism showed no association with SLE risk (TC vs CC: OR = 1.16, 95% CI = 0.91-1.48, PHeterogeneity (PH) = 0.579; TT vs CC: OR = 1.15, 95% CI = 0.63-2.09, PH = 0.003; T vs C: OR = 1.08, 95% CI = 0.8-1.45, PH = 0.003; TC/TT vs CC: OR = 1.17, 95% CI = 0.93-1.46, PH = 0.133; and TT vs TC/CC: OR = 1.06, 95% CI = 0.64-1.76, PH = 0.004). TGF-&#x3b2;1 G915C and T869C polymorphisms were not linked with SLE risk. Moreover, subgroup analysis stratified by ethnicity and Hardy-Weinberg equilibrium revealed no significant correlation of TGF-&#x3b2;1 T869C, C509T, G915C polymorphisms with SLE risk.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">TGF-&#x3b2;1 T869C, C509T, G915C polymorphisms might not be associated with the development of SLE.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 the Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Ning</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, South Branch of Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dai</LastName><ForeName>Yijun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Juanjuan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Meng</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Ling</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, South Branch of Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Fei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>He</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Qing</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0002-3949-2159</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053773">Transforming Growth Factor beta1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508960">TGFB1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005006" MajorTopicYN="N">Ethnicity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053773" MajorTopicYN="Y">Transforming Growth Factor beta1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>17</Day><Hour>11</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36930071</ArticleId><ArticleId IdType="pmc">PMC10019118</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000033321</ArticleId><ArticleId IdType="pii">00005792-202303170-00008</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol. 2003;56:481&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1769989</ArticleId><ArticleId IdType="pubmed">12835292</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Cruz D. Autoimmune diseases associated with drugs, chemicals and environmental factors. Toxicol Lett. 2000;112-113:421&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">10720762</ArticleId></ArticleIdList></Reference><Reference><Citation>Dooley MA, Hogan SL. Environmental epidemiology and risk factors for autoimmune disease. Curr Opin Rheumatol. 2003;15:99&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">12598794</ArticleId></ArticleIdList></Reference><Reference><Citation>Deapen D, Escalante A, Weinrib L, et al. . A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum. 1992;35:311&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">1536669</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsao BP. Update on human systemic lupus erythematosus genetics. Curr Opin Rheumatol. 2004;16:513&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">15314487</ArticleId></ArticleIdList></Reference><Reference><Citation>Moustakas A, Pardali K, Gaal A, et al. . Mechanisms of TGF-beta signaling in regulation of cell growth and differentiation. Immunol Lett. 2002;82:85&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">12008039</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubtsov YP, Rudensky AY. TGFbeta signalling in control of T-cell-mediated self-reactivity. Nat Rev Immunol. 2007;7:443&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">17525753</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohtsuka K, Gray JD, Stimmler MM, et al. . Decreased production of TGF-beta by lymphocytes from patients with systemic lupus erythematosus. J Immunol. 1998;160:2539&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">9498800</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker-Merok A, Eilertsen GO, Nossent JC. Levels of transforming growth factor-beta are low in systemic lupus erythematosus patients with active disease. J Rheumatol. 2010;37:2039&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">20682675</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin T, Almehed K, Carlsten H, et al. . Decreased serum levels of TGF-beta1 are associated with renal damage in female patients with systemic lupus erythematosus. Lupus. 2012;21:310&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">22072025</ArticleId></ArticleIdList></Reference><Reference><Citation>Elbeldi-Ferchiou A, Ben Ahmed M, Smiti-Khanfir M, et al. . Resistance to exogenous TGF-beta effects in patients with systemic lupus erythematosus. J Clin Immunol. 2011;31:574&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">21503670</ArticleId></ArticleIdList></Reference><Reference><Citation>Schotte H, Willeke P, Rust S, et al. . The transforming growth factor-beta1 gene polymorphism (G915C) is not associated with systemic lupus erythematosus. Lupus. 2003;12:86&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">12630751</ArticleId></ArticleIdList></Reference><Reference><Citation>Dang H, Geiser AG, Letterio JJ, et al. . SLE-like autoantibodies and Sj&#xf6;gren&#x2019;s syndrome-like lymphoproliferation in TGF-beta knockout mice. J Immunol. 1995;155:3205&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">7673733</ArticleId></ArticleIdList></Reference><Reference><Citation>Cambien F, Ricard S, Troesch A, et al. . Polymorphisms of the transforming growth factor-beta 1 gene in relation to myocardial infarction and blood pressure. The Etude Cas-T&#xe9;moin de l&#x2019;Infarctus du Myocarde (ECTIM) study. Hypertension. 1996;28:881&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8901839</ArticleId></ArticleIdList></Reference><Reference><Citation>Awad MR, El-Gamel A, Hasleton P, et al. . Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation. 1998;66:1014&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">9808485</ArticleId></ArticleIdList></Reference><Reference><Citation>Grainger DJ, Heathcote K, Chiano M, et al. . Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet. 1999;8:93&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">9887336</ArticleId></ArticleIdList></Reference><Reference><Citation>Caserta TM, Knisley AA, Tan FK, et al. . Genotypic analysis of the TGF beta-509 allele in patients with systemic lupus erythematosus and Sjogren&#x2019;s syndrome. Ann Genet. 2004;47:359&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">15581833</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu LY, Cheng HH, Sung PK, et al. . Single-nucleotide polymorphisms of transforming growth factor-beta1 gene in Taiwanese patients with systemic lupus erythematosus. J Microbiol Immunol Infect. 2004;37:145&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">15221033</ArticleId></ArticleIdList></Reference><Reference><Citation>Guarnizo-Zuccardi P, Lopez Y, Giraldo M, et al. . Cytokine gene polymorphisms in Colombian patients with systemic lupus erythematosus. Tissue Antigens. 2007;70:376&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">17711410</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B, Morinobu A, Kanagawa S, et al. . Transforming growth factor beta 1 gene polymorphism in Japanese patients with systemic lupus erythematosus. Kobe J Med Sci. 2007;53:15&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">17579298</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, et al. . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264&#x2013;9</Citation><ArticleIdList><ArticleId IdType="pubmed">19622511</ArticleId></ArticleIdList></Reference><Reference><Citation>Manolova II, Stanilova S. Gene polymorphisms of immunoregulatory cytokines IL-10 and TGF-&#x3b2;1 in systemic lupus erythematosus. In: Tech R, ed. Genes and Autoimmunity&#x2013;Intracellular Signaling and Microbiome Contribution; 2013.</Citation></Reference><Reference><Citation>Sayed SK, Galal SH, Herdan OM, et al. . Single nucleotide polymorphism T869C of transforming growth factor-beta 1 gene and systemic lupus erythematosus: association with disease susceptibility and lupus nephritis. Egypt J Immunol. 2014;21:9&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">25812349</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezaei A, Ziaee V, Sharabian FT, et al. . Lack of association between interleukin-10, transforming growth factor-beta gene polymorphisms and juvenile-onset systemic lupus erythematosus. Clin Rheumatol. 2015;34:1059&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">25633651</ArticleId></ArticleIdList></Reference><Reference><Citation>Dar SA, Janahi EM, Haque S, et al. . Superantigen influence in conjunction with cytokine polymorphism potentiates autoimmunity in systemic lupus erythematosus patients. Immunol Res. 2016;64:1001&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">26676360</ArticleId></ArticleIdList></Reference><Reference><Citation>Paradowska-Gorycka A, Roszak M, Stypinska B, et al. . IL-6 and TGF-beta gene polymorphisms, their serum levels, as well as HLA profile, in patients with systemic lupus erythematosus. Clin Exp Rheumatol. 2019;37:963&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">30943147</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo P, Liu S, Sun X, et al. . Association of TGF-ss1 polymorphisms and chronic hepatitis C infection: a meta-analysis. BMC Infect Dis. 2019;19:758.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6716859</ArticleId><ArticleId IdType="pubmed">31470810</ArticleId></ArticleIdList></Reference><Reference><Citation>Hristova M, Kamenarska Z, Dzhebir G, et al. . The role of IL-17 rs2275913, IL-17RC rs708567 and TGFB1 rs1800469 SNPs and IL-17A serum levels in patients with lupus nephritis. Rheumatol Int. 2021;41:2205&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">34554306</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Xiao L, Zhou Y, et al. . Association analysis of the promoter -509C/T gene polymorphisms of transforming growth factor-&#x3b2;1 with systemic lupus erythematosus in the Hans in Guizhou province. Chinese J Immunol. 2007;23:415&#x2013;7.</Citation></Reference><Reference><Citation>Martelossi Cebinelli GC, Paiva Trugilo K, Badaro Garcia S, et al. . TGF-beta1 functional polymorphisms: a review. Eur Cytokine Netw. 2016;27:81&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">28396298</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatt M, Kumar S, Siddiqui MH, et al. . Influence of cytokine gene polymorphism on the risk of rheumatic heart disease - A meta-analysis. Immunol Lett. 2018;194:69&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">29317215</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G, Hu C, Lai P, et al. . Association between TGF-beta1 rs1982073/rs1800469 polymorphism and lung cancer susceptibility: an updated meta-analysis involving 7698 cases and controls. Medicine (Baltim). 2019;98:e18028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6882652</ArticleId><ArticleId IdType="pubmed">31764821</ArticleId></ArticleIdList></Reference><Reference><Citation>Fayad A, Hassan E, Salem T. Melatonin receptor 1beta gene polymorphism rs10830963, serum melatonin, TNF-alpha, IL-6, IL-1beta, in Egyptian patients with systemic lupus erythematosus. Egypt J Immunol. 2019;26:101&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">31333000</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammadi S, Saghaeian Jazi M, Zare Ebrahimabad M, et al. . Interleukin 10 gene promoter polymorphisms (rs1800896, rs1800871 and rs1800872) and haplotypes are associated with the activity of systemic lupus erythematosus and IL10 levels in an Iranian population. Int J Immunogenet. 2019;46:20&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">30430731</ArticleId></ArticleIdList></Reference><Reference><Citation>Vira H, Pradhan V, Umare V, et al. . Role of polymorphisms in MMP-9 and TIMP-1 as biomarkers for susceptibility to systemic lupus erythematosus patients. Biomark Med. 2019;13:33&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">30561224</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>